By Cole Bunn, Senior Research Analyst, LSN
Angel investors are a major force at the earliest stages of financing for life science companies, and can have a great influence in startup development. As many of these individuals have been entrepreneurs and often take an operational role along with an investment, their capital, network and know-how is crucial for energizing a new venture and ensuring that the company has all its ducks in a row as it goes on to grow as a business and raise more capital.
Given the significant differences in the development and financing needs of biotech vs. medtech companies, LSN has two separate sessions which showcase active angles in each space separately.
The Biotech Angels panel will be moderated by Bernie Rudnick, Founder, Mid Atlantic Bio Angels and will feature the following panelists:
- Michael O’Donnell, Member, Life Science Angels
- Stephen MaCDonald, Managing Director, Bio/Med Investor Network
- Richard Koffler, CEO, Greenwings Biomedical
- John Chi, Head of Screening Committee, BioPacific Investors
The Medtech Angels panel will be moderated by Brian Frenzel, Member, Band of Angels and will feature the following panelists:
- Laird Cagan, Managing Director, Cagan McAfee Capital Partners
- Patricia Beckman, Managing Director, WINGS
- Chris Apfel, Member, Life Science Angels
- Wei Tao, Member, Sand Hill Angels
These panel sessions will explore general topics such as how angel groups approach an investment opportunity and how best to pitch to/work with an angel investor as well as more specific topics such as how they work with other angel groups and VCs, what to expect in the diligence process, cap table issues and more.
Next Phase Newsletter 